Skip to content
CompanySight
Company No. 03593973 · Incorporated 7 Jul 1998

Eurofins MGS Laboratories Limited

Registered name: EUROFINS MGS LABORATORIES LIMITED

Part of Eurofins Scientific Se group

Eurofins MGS Laboratories Limited made £1.5m revenue and a £34k loss in the year to 31 Dec 2025.

Eurofins MGS Laboratories Limited’s revenue grew 41% to £1.5m in the year to 31 Dec 2025, with a loss of £34k and 15 employees. The company is classified under “other professional, scientific and technical activities” and is based in Wolverhampton; we hold 3 years of its filed accounts.

Full P&L filedSection M · Professional, scientific and technical activitiesSIC 74909Other professional, scientific and technical activities n.e.c.
Status
Active
Location
Wolverhampton, West Midlands
Age
28 yrs · since 1998
Type
Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Dec 2025

Key figures

Doing more with less
Revenue
£1.5m
Growth ▲40.9%
Profit
−£34k
Growth —
Profit margin
−2.3%
Gross 85.7%
Employees
15
Change ▼16.7%
Profit / employee
−£2.3k
Revenue/employee £97.6k
Profitable streak
0yrs
Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

3 filed years

Financial history

Multi-year financials, oldest to newest
Year to31 Dec 202331 Dec 202431 Dec 2025
DisclosureFull P&LFull P&LFull P&L
Profit & loss
Revenue (turnover)£1.6m£1m£1.5m
Cost of sales−£138k−£215k−£209k
Gross profit£1.5m£824k£1.3m
Operating profit£33k−£310k£23k
Profit before tax−£13k−£360k−£23k
Profit after tax£97k−£395k−£34k
Profit (best available)£97k−£395k−£34k
Employees (average)201815
Ratios
Profit margin6.1%−38%−2.3%
Gross margin91.3%79.3%85.7%
Revenue per employee£79.8k£57.7k£97.6k
Profit per employee£4.8k−£21.9k−£2.3k
Growth (year on year)
Revenue growth—▼34.9%▲40.9%
Profit growth—▼507.2%—
Headcount growth—▼10%▼16.7%
Balance sheet — indirect signals, not revenue
Net assets———
SourceAccounts · bulk data Jun 2025Accounts · bulk data Jun 2025Accounts · bulk data Jun 2026
Derived from the latest filing

How the business works

Profit margin
−2.3%
Profit ÷ revenue.
Gross margin
85.7%
Gross profit ÷ revenue. High for software and services.
Revenue per employee
£97.6k
Revenue ÷ average employees.
Profit per employee
−£2.3k
Profit ÷ average employees.
Cash conversion
—
Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue
—
Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue
—
Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue
—
Money owed by customers. Low = customers pay quickly.
Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets
—
Now —
Cash at bank
—
Now —
Headcount
▼17%
Now 15
Deferred income
—
Now —
Fixed assets
—
Now —
Corporate ownership

Group structure

Ownership chain

  1. Eurofins Scientific Se (registered outside the UK register)ultimate parent75–100%
  2. Eurofins Biopharma Product Testing UK Holding Limited75–100%
  3. Eurofins MGS Laboratories Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Sister companies (1)

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Latest figures from accounts for the year to 31 Dec 2025 (profit −£34k), from the Companies House accounts bulk data published Jun 2026. Spotted an error? Request a correction.

Updated from Companies House on 13 Oct 2026

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.